Aldeyra Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 10
- Market Cap
- $319M
- Website
- http://www.aldeyra.com
- Introduction
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Clinical Trials
34
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06685692
- Locations
- 🇺🇸
Florida Health Sciences Center/Tampa General Hospital/USF, Tampa, Florida, United States
🇺🇸The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇺🇸UDL Clinical Research, LLC, Houston, Texas, United States
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT06493604
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Vehicle ophthalmic solution
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT06424444
- Locations
- 🇺🇸
Core, Inc., Shelby, North Carolina, United States
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT06389214
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ADX-629 (Open-label)
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05717920
- Locations
- 🇺🇸
Bexley Dermatology Research, Bexley, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
FDA Accepts Aldeyra's Reproxalap NDA for Dry Eye Disease with AbbVie Collaboration
The FDA has accepted Aldeyra Therapeutics' New Drug Application (NDA) for reproxalap, a topical ocular therapy for dry eye disease, with a PDUFA date of April 2, 2025.
FDA Accepts Aldeyra's Reproxalap NDA for Dry Eye Disease, Expands AbbVie Partnership
The FDA has accepted for review Aldeyra Therapeutics' resubmitted NDA for reproxalap, a novel drug for treating dry eye disease, with a PDUFA date of April 2, 2025.